Intervention
ABBV-400
ClinicalTrials.gov intervention label
How to interpret these research links
Connected source recordsThis is the original ClinicalTrials.gov intervention label, found in 2 distinct published trials. Registry interventions may represent drugs, devices, procedures or other study activities. A matched term or study association does not establish product equivalence, efficacy or regulatory approval.
Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.
Advertisement
Clinical trials
2 shownStudy to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400NCT06084481 · 2023-11-09
RECRUITINGStudy to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 as Monotherapy and in Combination With IV BevacizumabNCT05029882 · 2021-10-13
ACTIVE_NOT_RECRUITINGCommon conditions
Advanced Solid Tumors1Biliary Tract Cancers1Colorectal Cancer1Esophageal Squamous Cell Carcinoma1Gastroesophageal Adenocarcinoma1Head and Neck Squamous-Cell Carcinoma1Hepatocellular Carcinoma1Hormone Receptor+/Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer1Non-Small Cell Lung Cancer1Pancreatic Ductal Adenocarcinoma1Platinum Resistant High Grade Epithelial Ovarian Cancer1Triple Negative Breast Cancer1
Leading sponsors
Trial status mix
ACTIVE_NOT_RECRUITING1
RECRUITING1
Phase mix
PHASE12
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.